Cardiac biomarkers response under angiotensin receptor-neprilysin inhibitor: a sub-analysis of the NATRIUM-HF study. [PDF]
ESC Heart FailBruno J +15 more
europepmc +1 more source
The effectiveness and safety of sacubitril/valsartan in real-world dialysis patients with heart failure reduced ejection fraction. [PDF]
Medicine (Baltimore)Tu KC, Weng YC, Liao CT, Wu JY.
europepmc +1 more source
Pharmacophore-Based Identification and Molecular Characterization of Potent Neprilysin Inhibitors: Biochemical and Therapeutic Implications for Cardiovascular Diseases. [PDF]
Chem Biol Drug DesKuo CT, Wu YC, Li JM, Ju TC, Tseng TS.
europepmc +1 more source
In Vivo Inhibition of Dipeptidyl Peptidase 4 and Neprilysin Activity Enables Measurement of GLP-1 Secretion in Male Rats. [PDF]
J Endocr SocGalsgaard KD +4 more
europepmc +1 more source
Bleeding Disorder, A Newly Recognized Adverse Event Following Sacubitril/Valsartan Therapy. [PDF]
Eur J Case Rep Intern MedAl-Omari YW +3 more
europepmc +1 more source
Retraction: The angiotensin receptor neprilysin inhibitor LCZ696 attenuates renal fibrosis via ASK1/JNK/p38 MAPK-mediated apoptosis in unilateral ureteral obstruction. [PDF]
PLoS OnePLOS One Editors.
europepmc +1 more source
Bibliometric analysis of sacubitril/valsartan in the management of chronic kidney disease (2013-2025). [PDF]
Ren FailLiu P, He X, Luo X, Xie S, Li Y, Su B.
europepmc +1 more source
Japanese Nationwide Survey of New Heart Failure Drug Prescriptions by Pediatric Cardiologists. [PDF]
Circ RepMuneuchi J, Collaborators.
europepmc +1 more source
Sacubitril/valsartan fails to prevent doxorubicin-induced cognitive impairment and hippocampal oxidative, inflammatory, and apoptotic alterations in rats. [PDF]
Front PharmacolAlresheedi MM, Aldubayan MA.
europepmc +1 more source